Compare Novartis AG (NVS) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Novartis AG trades at $153.53 (market cap $298.18B), while YieldMax Universe Fund of Option Income ETFs trades at $7.65. The key difference: Novartis AG pays a 3.02% dividend while YieldMax Universe Fund of Option Income ETFs pays none, and Novartis AG is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| NVS | YMAX | |
|---|---|---|
Market Cap | $298.18B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $168.62 | $13.26 |
52-Week Low | $119.31 | $7.27 |
Enterprise Value | $339.50B | — |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
YMAX trades at $7.70, up 1.58% today, with a neutral technical signal and bearish moving averages. Recent news highlights weekly dividend distributions, though a 24/7 Wall Street article on July 14, 2026, notes shrinking payouts and a 1.33% fee structure. The stock lacks disclosed financial ratios, limiting fundamental clarity.
The outlook is mixed, with income appeal from dividends offset by fee concerns and opaque fundamentals. Risks include cost inefficiencies and reliance on market volatility for returns, while technicals suggest near-term consolidation around $8 support/resistance levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
